Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...

The fully AI-led Diabetes Prevention Program (DPP) intervention was non-inferior to the traditional human-coached program for weight loss and glucose control. The AI-led program had significantly ...

An AI-powered lifestyle intervention app for prediabetes reduced the risk of diabetes similarly to traditional, human-led programs in adults in a recent study, researchers from Johns Hopkins Medicine ...

Researchers from Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health report that an AI-powered lifestyle intervention app for prediabetes reduced the risk of diabetes ...

Embark on a fulfilling pharmacy career with our Pharmacy Technician Training Program. Our 16-week program allows you to gain the skills required for safe patient care. The self-paced format ensures ...

– DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 – – New ...

Tulisokibart, an investigational anti-TL1A monoclonal antibody currently in Phase 3 trials for ulcerative colitis and Crohn’s disease, to be studied in hidradenitis suppurativa, radiographic axial ...

Phocuswright today announced the full program for The Phocuswright Conference 2025, the travel industry’s most important stage where global leaders, bold disruptors, and rising innovators converge to ...

Fort Lee, NJ, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the ...

GameSpot may get a commission from retail offers. With the Battlefield 6 open beta fast approaching, players looking forward to dropping into Battlefield's next big battle may want to play a few ...